Director, Medical Science Liaison (Boston, RI, NH, VT, ME, CT(Yale))

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$236K-$259K Verified - from the job posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$81,444 U.S. median for this role

Projected growth (BLS Employment Projections)

+6.9% - Faster than average

204% above the BLS role benchmark for healthcare aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 29-1141 - Healthcare aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage Verified - from the job posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Medical Science Liaison (Boston, RI, NH, VT, ME, CT(Yale)) Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses. Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.